SII CEO Adar Poonawalla Buys The Most Expensive Property In London

SII CEO Adar Poonawalla Buys The Most Expensive Property In London

London: Adar Poonawalla, the CEO of the Serum Institute of India (SII), has made a significant foray into the world of luxury real estate with the purchase of the Mayfair Mansion on Hill Street in London. This high-profile acquisition has raised eyebrows, not just for its opulence but also for the substantial price tag attached to it—reportedly around 14 million euros, making it one of the most expensive residential properties acquired in 2023.

Situated in the prestigious Mayfair district, the Mayfair Mansion is a historic gem, dating back to 1920, and spans an impressive 25,000 square feet. Poonawalla secured this extravagant property through Serum Life Sciences, SII’s UK-based subsidiary. The deal also included a guest house and the charming secret garden of Mayfair. Notably, the mansion ranks as the second-most expensive property in London, with the Rutland Gate Mansion topping the charts after being purchased for a whopping 21 million euros by a Saudi Arabian businessman in 2020.

The mansion itself is a testament to luxury, featuring six spacious bedrooms, a sprawling swimming pool, and elegant guest seating areas. The property exudes historical charm while offering modern amenities, creating a unique blend of classic and contemporary.

Apart from serving as a vacation residence for the Poonawalla family during their visits to London, the Mayfair Mansion is poised to become the operational centre for Serum Life Sciences. This strategic decision aligns with SII’s global outlook and aims to leverage the property for hosting corporate events and programs, further strengthening its international business presence.

A spokesperson for the Poonawalla family clarified that while the mansion will play a multifaceted role in their lives, including business functions and vacations, there are no plans for permanent relocation to London. Adar Poonawalla, who assumed the role of CEO of the Serum Institute of India in 2011, has been instrumental in leading the institute’s growth and prominence on the global stage. SII gained worldwide acclaim for its pivotal role in developing and mass-producing the COVID-19 vaccine during the global pandemic.

The Mayfair Mansion acquisition marks a strategic move, reflecting SII’s commitment to global engagement and its continued position as a major player in international vaccine development and manufacturing.